Moderna (MRNA) Could Offset COVID Revenue via Rare Diseases - Morgan Stanley
Tweet Send to a Friend
Morgan Stanley analyst Matthew Harrison reiterated an Equalweight rating and $199.00 price target on Moderna (NASDAQ: MRNA) after performing a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
